Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibin subunit beta E (INHBE) mRNA is the transcript encoding the hepatokine Activin E, a member of the transforming growth factor-beta (TGF-beta) superfamily. Synthesized primarily in the liver, Activin E is secreted into circulation and acts on ALK7 (ACVR1C) receptors on adipocytes to suppress lipolysis and promote lipid storage, thereby regulating energy homeostasis and fat distribution. Human genetic studies have shown that individuals carrying naturally occurring loss-of-function variants in the INHBE gene exhibit a healthier metabolic profile, characterized by reduced visceral fat, lower triglyceride levels, and a decreased risk of type 2 diabetes and cardiovascular disease. Consequently, INHBE mRNA has emerged as a highly promising therapeutic target for the treatment of obesity and metabolic disorders.
Therapeutic strategies targeting INHBE mRNA primarily utilize RNA interference (RNAi) to selectively silence the gene in hepatocytes. Investigational small interfering RNA (siRNA) drugs, such as WVE-007, ARO-INHBE, CMS-D008, SRSD384, RBD3133, IBI3046, and RN3161, are designed to bind to and degrade INHBE mRNA. This knockdown reduces circulating Activin E levels, disinhibiting lipolysis and promoting fat-specific weight loss while preserving lean muscle mass. This muscle-sparing profile represents a significant advantage over traditional GLP-1 receptor agonists, which are often associated with muscle loss. Clinical trials are currently evaluating these siRNA candidates both as monotherapies and in combination with incretin-based therapies to achieve synergistic and durable metabolic improvements.
Small interfering RNA (siRNA) mediated gene silencing leading to mRNA degradation and reduction of hepatic INHBE expression
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibin subunit beta E mRNA (INHBE mRNA).